Podophyllotoxin derivatives: Current synthetic approaches for new anticancer agents

Current Pharmaceutical Design

Volumn 11, Issue 13, 2005, Pages 1695-1717

  You, Youngjae ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Antimitotic agents; Etoposide; Podophyllotoxin; Prodrugs; Structure activity relationship; Topoisomerase II

Indexed keywords

1,3 DIOXOLANE DERIVATIVE; 2'' DEOXY 2'' (DIMETHYLAMINO)ETOPOSIDE; 3',4' DIDEMETHOXY 3',4' DIOXOPODOPHYLLOTOXIN DERIVATIVE; 3',4' O DIDEMETHOXY EPIPODOPHYLLOTOXIN DERIVATIVE; 4 AZA 2,3 DEHYDRO 4 DEOXYPODOPHYLLOTOXIN DERIVATIVE; 4 AZA 2,3 DEHYDROPODOPHYLLOTOXIN DERIVATIVE; 4 METHYLENE 4 DEOXYPODOPHYLLOTOXIN; 4' NOR 4 DEOXYPODOPHYLLOTOXIN; 4' NORPODOPHYLLOTOXIN; 4BETA O N [2 (N',N' DIALKYLAMINO)ALKYL]CARBAMATE DERIVATIVE; ALPHA CONIDENDRIN; ALPHA PELTATIN; ANTIBODY; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; AZATOXIN; BENZOPHENONE DERIVATIVE; BETA PELTATIN; CARBAMIC ACID DERIVATIVE; DEOXYPODOPHYLLOTOXIN; DIOXANE DERIVATIVE; DIPROPHYLLINE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; ETOPOFOS; ETOPOSIDE; ETOPOSIDE DERIVATIVE; FORMOSOLACTONE; GL 331; GLYCOSIDE; HEXAHYDROPYRIDO[1,2 B]ISOQUINOLINE DERIVATIVE; HEXAHYDROPYRROLO[1,2 B]ISOQUINOLINE DERIVATIVE; HYDROXYPODOPHYLLOTOXIN; ISOQUINOLINE DERIVATIVE; JUSTICIDIN B; JUSTICIDIN E; LIGNAN DERIVATIVE; N AMINOPODOPHYLLOTOXIN; NAPHTHALENE DERIVATIVE; NATURAL PRODUCT; PACLITAXEL; PHENAZINE DERIVATIVE; PICROPODOPHYLLIN; PODOPHYLLIN; PODOPHYLLOTOXIN; PODOPHYLLOTOXIN DERIVATIVE; PRODRUG; PYRIDO[1,2 B]ISOQUINOLINE DERIVATIVE; PYRROLO[1,2 B]ISOQUINOLINE DERIVATIVE; QUINOXALINE DERIVATIVE; RETRO 4' NOR 4 EPIPODOPHYLLOTOXIN; RETROCHINENSIN; RETROETOPOSIDE; RETROJUSTICIDIN B; SIKKIMOTOXIN; SULFIDE; TENIPOSIDE; TETRALIN DERIVATIVE; TOP 53; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER; CANCER RESISTANCE; CATALYSIS; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG HYDROLYSIS; DRUG MECHANISM; DRUG METABOLISM; DRUG RELEASE; DRUG RESEARCH; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; MITOSIS INHIBITION; NAUSEA; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; PODOPHYLLOTOXIN; PRODRUGS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 18744373344     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612053764724     Document Type: Review

References (194)

1. Bishop JF, Lowenthal RM, Joshua D, Matthews JP, Todd D, Cobcroft R, et al. Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group. Blood 1990; 75: 27-32.
2. Rivera G, Bowman WP, Murphy SB, Dahl GV, Aur RJ, Kalwinsky DK, et al. VM-26 with prednisone for treatment of refractory acute lymphocytic leukemia. MedPediatr Oncol 1982; 10: 439-45,
3. Bosl GJ, Geller NL, Bajorin, D. A randomized trial of etoposide +cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good prognosis germ cell tumors. J Clin Oncol 1988; 6: 1231-6.
4. Johnson DH. Management of small cell lung cancer: current state of the art. Chest 1999; 116 (Suppl. 3): 525-30.
5. Sparano JA, Wiernik PH, Leaf A, Dutcher JP. Infusional cyclophosphamide, doxorubicin, and etoposide in relapsed and resistant non-Hodgkin's lymphoma: evidence for a schedule-dependent effect favoring infusional administration of chemotherapy. J Clin Oncol 1993; 11: 1071-9
6. Salles G, Shipp MA, Coiffer B. Chemotherapy of non-Hodgkin aggressive lymphomas. Sem Oncol 1994; 31: 46-54.
7. Hartwell JL, Schrecker AW. The chemistry of podophyllin. Foster Chem Org Naturst 1958; 15: 83.
8. Stähelin H, von Wartburg A. From podophyllotoxin glycoside to etoposide. Prog Drug Res 1989; 33, 169-267.
9. Stähelin H, von Wartburg A. The chemical and biological route from podophyllotoxin to etoposide. Cancer Res 1991; 51, 5-15.
10. Imbert TF. Discovery of podophyllotoxins. Biochimie 1998; 80, 207-22.
11. Ward RS. Synthesis of podophyllotoxin and related compounds. Synthesis 1992; 719-30.
12. Ramos AC, De Clairac RP-L, Medarde M. Heterolignans. Heterocycles 1999; 51: 1443-70.
13. Botta B, Delle Monache G, Mesiti D, Vitali A, Zappia G. Aryltetralin lignans: chemistry, pharmacology and biotransformations. Curr Med Chem 2001; 8: 1363-81.
14. Damayanthi Y, Lown JW. Podophyllotoxins: current status and recent developments. Curr Med Chem 1998; 5: 205-52.
15. Gordaliza M, Castro MA, del Corral JM, Feliciano AS. Antitumor properties of podophyllotoxin and related compounds. Curr Pharm Dos 2000; 6: 1811-39.
16. Sackett DL. Podophyllotoxin, steganacin and combretastatin: natural products that bind at the colchicine site of tubulin. Pharmacol Ther 1993; 59: 163-228.
17. Desbène S, Giorgi-Renault S. Drugs that inhibit tubulin polymerization: the particular case of podophyllotoxin and analogues. Curr Med Choro Anti-Canc Agents 2002; 2: 71-90.
18. Kelly MG, Hartwell JL. The biological effects and the chemical composition of podophyllin. J Natl Cancer Inst 1954; 14: 967-1010.
19. Podwyssotzki V. Pharmakologische studien über Podophyllun peltatum. Arch Exp Pathol Pharmakol 1880; 13: 29-52.
20. Podwyssotzki V. The active consituent of podophyllin. Pharm J Trans 1881; 12: 217-8.
21. Podwyssotzki V. On the active constituents of podophyllin. Am J Pharm 1882; 12: 102-15.
22. Borsche W, Niemann J. Podophyllin. Justus Liebigs Ann Chem 1932; 494: 126-42.
23. Späth E, Wessely F, Kornfeld L. Über die konstitution von podophyllotoxin und pikro-podophyllin. Chem Ber 1932; 65: 1536-49.
24. Späth E, Wessely F, Nadler E. Zur konstitution dos podophyllotoxin und picro-podophyllins. Chem Ber 1932; 65: 1773-7.
25. Hartwell JL, Schrecker AW. Components of podophyllin. V. The constitution of podophyllotoxin. J Am Chem Soc 1951; 73: 2909-16.
26. Schrecker AW, Hartwell JL. Components of podophyllin. XX. The absolute configuration of podophyllotoxin and related lignans. J Org Chem 1956; 21: 381-2.
27. Gensler WJ, Gatsonis CD. Synthesis of podophyllotoxin. J Am Chem Soc 1962; 84: 1748-9.
28. Gensler WJ, Gatsonis CD. Synthesis of podophyllotoxin. J Org Chem 1966; 31: 4004-8.
29. Kalpan IW. Condylomata acuminata. New Orleans Med Surg J 1942; 94: 388-95.
30. King IS, Sullivan M. The similarity of the effects of posophyllin and colchicine and their use in treatment of Condylomata acuminata. Science 1946; 104: 244-5.
31. Sullivan BJ, Weshler HI. The cytological effects of podophyllin. Science 1947; 105: 433.
32. Belkin M. Effects of podophyllin on transplanted mouse tumor. Fed Proc 1947; 6: 308.
33. Sullivan M, King LS. Effect of resin of Podophyllum on normal skin, Condylomata acuminata, and Verrucae vulgares. Arch Demat Syph 1947; 56: 30-47.
34. Hartwell JL, Shear MJ. Chemotherapy of cancer: classes of compounds under investigation, and active components of podophyllin. Cancer Res 1947; 7: 716-7.
35. von Wartburg A, Stahelin H. In: Lednicer D Ed, Chronicle of drug discovery. Washington DC, ACS. 1993; 3: 349-80.
36. Long BH, Minocha A. Inhibition of topoisomerase II by VP-16-213 (etoposide), VM-26 (teniposide), and structural congeners as an explanation for in vivo DNA breakage and cytotoxicity. Proc Am Ass Cancer Res 1983; 24: 321.
37. Minocha A, Long BH. Inhibition of the DNA catenation activity of type II topoisomerase by VP16-213 and VM-26. Biochem Biophys Res Commun 1984; 122: 165-70.
38. Long BH, Musial ST, Brattain MG. Comparison of cytotoxicity and DNA breakage activity of congeners of podophyllotoxin including VP16-213 and VM26: a quantitative structure-activity relationship. Biochemistry 1984; 23: 1183-8.
39. Terada T, Fujimoto K, Nomura M, Yamashita J, Kobunai T, Takeda S, et al. Antitumor agents. I. DNA topoisomerase II inhibitory activity and the structural relationship of podophyllotoxin derivatives as antitumor agents. Chem Pharm Bull 1992; 40: 2720-7.
40. Loike JD, Horwitz SB. Effects of podophyllotoxin and VP-16-213 on microtubule assembly in vitro and nucleoside transport in HeLa cells. Biochemistry 1976; 15: 5435-43.
41. Stahelin H. Activity of a new glycosidic lignan derivative (VP 16-213) related to podophyllotoxin in experimental tumors. Eur J Cancer 1973; 9: 215-21.
42. Seidlova-Masinova V, Malinsky J, Santavy F. The biological effects of some podophyllin compounds and their dependence on chemical structure. J Natl Cancer Inst 1957; 18: 359-71.
43. Lin CM, Kang GJ, Roach MC, Jiang JB, Hesson DP, Luduena RF, et al. Investigation of the mechanism of the interaction of tubulin with derivatives of 2-styrylquinazolin-4(3 H)-one. Pharmacol 1991; 40: 827-32.
44. Abal M, Andreu JM, Barasoain I. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr Cancer Drug Targets 2003; 3: 193-203.
45. Rothermel J, Wartmann M, Chen T, Hohneker J. EPO906 (epothilone B): a promising novel microtubule stabilizer. Semin Oncol 2003; 30, 51-5.
46. van Maanen JM, Retèl J, de Vries J, Pinedo HM. Mechanism of action of antitumor drug etoposide: a review. J Natl Cancer Inst 1988; 80: 1526-33.
47. Long BH, Musial ST, Brattain MG. Single- and double-strand DNA breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide. Cancer Res 1985; 45, 3106-12.
48. Long BH, Musial ST, Brattain MG DNA breakage in human lung carcinoma cells and nuclei that are naturally sensitive or resistant to etoposide and teniposide. Cancer Res 1986; 46, 3809-16.
49. Glisson BS, Smallwood SE, Ross WE. Characterization of VP-16-induced DNA damage in isolated nuclei from L1210 cells. Biochim Biophys Acta 1984; 783: 74-9.
50. Ross W, Rowe T, Glisson B, Yalowich J, Liu L. Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. Cancer Res 1984; 44: 5857-60.
51. Chen GL, Yang L, Rowe TC, Halligan BD, Tewey KM, Liu LF. Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 1984; 259: 13560-6.
52. Rowe T, Kupfer G, Ross W. Inhibition of epipodophyllotoxin cytotoxicity by interference with topoisomerase-mediated DNA cleavage. Biochem Pharmacol 1985; 34: 2483-7.
53. Thurston LS, Irie H, Tani S, Han FS, Liu ZC, Cheng YC, et al. Antitumor agents. 78. Inhibition of human DNA topoisomerase II by podophyllotoxin and alpha-peltatin analogues. J Med Chem 1986; 29: 1547-50.
54. Yang L, Rowe TC, Liu LF. Identification of DNA topoisomerase II as an intracellular target of antitumor epipodophyllotoxins in simian virus 40-infected monkey cells. Cancer Res 1985; 45: 5872-6.
55. Nelson EM, Tewey KM, Liu LF. Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4′-(9-acridinylamino)-methanesulfon-m-anisidide. Proc Natl Acad Sci USA 1984; 81: 1361-5.
56. Tewey KM, Chen GL, Nelson EM, Liu LF. Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 1984; 259: 9182-7.
57. van Maanen JM, Lafleur MV, Mans DR, van den Akker E, de Ruiter C, Kootstra PR, et al. Effects of the ortho-quinone and catechol of the antitumor drug VP-16-213 on the biological activity of single-stranded and double-stranded phi X174 DNA. Biochem Pharmacol 1988; 37: 3579-89.
58. Mac Donald TL, Lehnert EK, Loper JT, Chow KC, Ross WE. In: Potmesil M, Kohn KW Eds, DNA topoisomerase in cancer. New York, Oxford University Press 1991; 119-214.
59. Saito H, Yoshikawa H, Nishimura Y, Kondo S, Takeuchi T, Umezawa H. Studies on lignan lactone antitumor agents. II. Synthesis of N-alkylamino- and 2, 6-dideoxy-2-aminoglycoside lignan variants related to podophyllotoxin. Chem Pharm Bull 1986; 34: 3741-6.
60. Hanauske AR, Wuster KC, Lehmer A, Rotter M, Schneider P, Kaeser-Frohlich A, et al. Activity of NK 611, a new epipodophyllotoxin derivative, against colony forming units from freshly explanted human tumours in vitro. Eur J Cancer 1995; 31A: 1677-81.
61. Mross K, Huttmann A, Herbst K, Hanauske AR, Schilling T, Manegold C, et al. Pharmacokinetics and pharmacodynamics of the new podophyllotoxin derivative NK 611. A study by the AIO groups PHASE-I and APOH. Cancer Chemother Pharmacol 1996; 38: 217-24.
62. Wang ZQ, Kuo YH, Schnur D, Bowen JP, Liu SY, Han FS, et al. Antitumor agents. 113. New 4 beta-arylamino derivatives of 4′-O-demethylepipodophyllotoxin and related compounds as potent inhibitors of human DNA topoisomerase II. J Med Chem 1990; 33: 2660-6.
63. Lee CC, Huang TS. A novel topoisomerase II poison GL331 preferentially induces DNA cleavage at (C/G)T sites and can cause telomere DNA damage. Pharm Res 2001; 18: 846-51.
64. Huang TS, Lee CC, Chao Y, Shu CH, Chen LT, Chen LL, et al. A novel podophyllotoxin-derived compound GL331 is more potent than its congener VP-16 in killing refractory cancer cells. Pharm Res 1999; 16: 997-1002.
65. Leteurtre F, Madalengoitia J, Orr A, Guzi TJ, Lehnert E, Macdonald T, et al. Rational design and molecular effects of a new topoisomerase II inhibitor, azatoxin. Cancer Res 1992; 52: 4478-83.
66. Cline SD, Macdonald TC, Osheroff N. Azatoxin is a mechanistic hybrid of the topoisomerase II-targeted anticancer drugs etoposide and ellipticine. Biochemistry 1997; 36: 13095-101.
67. Solary E, Leteurtre F, Paull KD, Scudiero D, Hamel E, Pommier Y. Dual inhibition of topoisomerase II and tubulin polymerization by azatoxin, a novel cytotoxic agent. Biochem Pharmacol 1993; 45: 2449-56.
68. Utsugi T, Shibata J, Sugimoto Y, Aoyagi K, Wierzba K, Kobunai T, et al. Antitumor activity of a novel podophyllotoxin derivative (TOP-53) against lung cancer and lung metastatic cancer. Cancer Res 1996; 56: 2809-14.
69. Yoshida M, Kobunai T, Aoyagi K, Saito H, Utsugi T, Wierzba K, et al. Specific distribution of TOP-53 to the lung and lung-localized tumor is determined by its interaction with phospholipids. Clin Cancer Res 2000; 6: 4396-401.
70. Byl JA, Cline SD, Utsugi T, Kobunai T, Yamada Y, Osheroff N. DNA topoisomerase II as the target for the anticancer drug TOP-53: mechanistic basis for drug action. Biochemistry 2001; 40: 712-8.
71. MacRae WD, Hudson JB, Towers GH. The antiviral action of lignans. Planta Med 1989; 55: 531-5.
72. Cho SJ, Kashiwada Y, Bastow KF, Cheng YC, Lee KH. Antitumor agents. 164. Podophenazine, 2″, 3″-dichloropodophenazine, benzopodophenazine, and their 4 beta-p-nitroaniline derivatives as novel DNA topoisomerase II inhibitors. J Med Chem 1996; 39: 1396-402.
73. Bertounesque E, Imbert T, Monneret C. Synthesis of podophyllotoxin A-ring pyridazine analogue. Tetrahedron 1996; 52: 14235-46.
74. Wang ZQ, Hu H, Chen HX, Cheng YC, Lee KH. Antitumor agents. 124. New 4 beta-substituted aniline derivatives of 6, 7-O, O-demethylene4′-O-demethylpodophyllotoxin and related compounds as potent inhibitors of human DNA topoisomerase II. J Med Chem 1992; 35: 871-7.
75. Kamal A, Atchison K, Daneshtalab M, Micetich RG. Synthesis of podophyllotoxin congeners as potential DNA topoisomerase II inhibitors. Anticancer Drug Des 1995; 10: 545-54.
76. Castro A, del Corral JM, Gordaliza M, Grande C, Gomez-Zurita A, Garcia-Gravalos D, et al. Synthesis of podophyllotoxin congeners as potential DNA topoisomerase II inhibitors. Eur J Med Chem 2003; 38: 65-74.
77. Beers SA, Imakura Y, Dai HJ, Li DH, Cheng YC, Lee KH. Antitumor agents, 99. Synthetic ring C aromatized podophyllotoxin analogues as potential inhibitors of human DNA topoisomerase II. J Nat Prod 1988; 51: 901-5.
78. Jurd L. Heterocyclic benzodioxole lactones. J Heterocyl Chem 1996; 33: 1227-32.
79. Hitotsuyanagi Y, Ichihara Y, Takeya K, Itokawa H. Synthesis of 4-oxa-2-azapodophyllotoxin, a novel analog of the antitumor lignan podophyllotoxin. Tetrahedron Lett 1994; 35: 9401-2.
80. Roulland E, Magiatis P, Arimondo P, Bertounesque E, Monneret C. Hemi-synthesis and biological activity of new analogues of podophyllotoxin. Bioorg Med Chem 2002; 10: 3463-71.
81. Liu SY, Hwang BD, Haruna M, Imakura Y, Lee KH, Cheng YC. Podophyllotoxin analogs: effects on DNA topoisomerase II, tubulin polymerization, human tumor KB cells, and their VP-16-resistant variants. Mol Pharmacol 1989; 36: 78-82.
82. Chang JY, Han FS, Liu SY, Wang ZQ, Lee KH, Cheng YC. Effect of 4 beta-arylamino derivatives of 4′-O-demethylepipodophyllotoxin on human DNA topoisomerase II, tubulin polymerization, KB cells, and their resistant variants. Cancer Res 1991; 51: 1755-9.
83. Lee KH, Imakura Y, Haruna M, Beers SA, Thurston LS, Dai HJ, et al. Antitumor agents, 107. New cytotoxic 4-alkylamino analogues of 4′-demethyl-epipodophyllotoxin as inhibitors of human DNA topoisomerase II. J Nat Prod 1989; 52: 606-13.
84. Lee KH, Beers SA, Mori M, Wang ZQ, Kuo YH, Li L, et al. Antitumor agents. 111. New 4-hydroxylated and 4-halogenated anilino derivatives of 4′-demethylepipodophyllotoxin as potent inhibitors of human DNA topoisomerase II. J Med Chem 1990; 33: 1364-8.
85. Hu H, Wang ZQ, Liu SY, Cheng YC, Lee KH. Antitumor agents. 123. Synthesis and human DNA topoisomerase II inhibitory activity of 2′-chloro derivatives of etoposide and 4 beta-(arylamino)-4′- O-demethylpodophyllotoxins. J Med Chem 1992; 35: 866-71.
86. Zhang YL, Guo X, Cheng YC, Lee KH. Antitumor agents. 148. Synthesis and biological evaluation of novel 4 beta-amino derivatives of etoposide with better pharmacological profiles. J Med Chem 1994; 37: 446-52.
87. Xiao Z, Xiao YD, Feng J, Golbraikh A, Tropsha A, Lee KH. Antitumor agents. 213. Modeling of epipodophyllotoxin derivatives using variable selection k nearest neighbor QSAR method. J Med Chem 2002; 45: 2294-309.
88. VanVliet DS, Tachibana Y, Bastow KF, Huang ES, Lee KH. Antitumor agents. 207. Design, synthesis, and biological testing of 4 beta-anilino-2-fluoro-4′-demethylpodophyllotoxin analogues as cytotoxic and antiviral agents. J Med Chem 2001; 44: 1422-8.
89. Zhou XM, Wang ZQ, Chen HX, Cheng YC, Lee KH. Antitumor agents. 125. New 4 beta-benzoylamino derivatives of 4′-O-demethyl-4-desoxypodophyllotoxin and 4 beta-benzoyl derivatives of 4′-O-demethylpodophyllotoxin as potent inhibitors of human DNA topoisomerase II. Pharm Res 1993; 10: 214-9.
90. Pan JL, Wang Z, Chen YZ. Synthesis of epipodophyllotoxin carboxylates and antitumor activity in vitro. Acta Pharmaceutica Sinica 1997; 32: 898-901.
91. Kamal A, Ashwini Kumar B, Arifuddin M, Dastidar SG. Synthesis of 4beta-amido and 4beta-sulphonamido analogues of podophyllotoxin as potential antitumour agents. Bioorg Med Chem 2003; 11: 5135-42.
92. Cragg G, Suffness M. Metabolism of plant-derived anticancer agents. Pharmacol Ther 1988; 37: 425-61.
93. Gensler WJ, Gatsonis CD. The podophyllotoxin-picropodophyllin equilibrium. J Org Chem 1966; 31: 3224-7.
94. Pearce HL, Bach NJ, Cramer TL. Synthesis of 2-azapodophyllotoxin. Tetrahedron Lett 1989; 30: 907-10.
95. Tomioka K, Kubota Y, Koga K. Synthesis and antitumor activity of podophyllotoxin aza-analogues. Tetrahedron Lett 1989; 30: 2953-4.
96. Gensler WJ, Murthy CD, Trammell MH. Nonenolizable podophyllotoxin derivatives. J Med Chem 1977; 20: 635-44.
97. 1H NMR spectra, and activity of delactonized derivatives of the anticancer drug etoposide. J Med Chem 1982; 25: 1077-81.
98. Glinski MB, Freed JC, Durst T. Preparation of 2-substituted podophyllotoxin derivatives. J Org Chem 1987; 52: 2749-53.
99. Wang JZ, Tian X, Tsumura H, Shimura K, Ito H. Antitumor agents. 207. Design, synthesis, and biological testing of 4beta-anilino-2-fluoro-4′-demethylpodophyllotoxin analogues as cytotoxic and antiviral agents. Anticancer Drug Des 1993; 8:193-202.
100. Kadow JF, Vyas DM, Doyle TW. Synthesis of etoposide lactam via a mitsunobu reaction sequence. Tetrahedron Lett 1989; 30: 3299-302.
101. Ward RS. Lignans, neolignans and related compounds. Nat Prod Rep 1997; 14: 43-74.
102. Ward RS. Lignans, neolignans and related compounds. Nat Prod Rep 1999; 16: 75-96.
103. Stevenson R, Holmes TL. Arylnaphthalene lignans. Synthesis of justicidin E, taiwanin C, dehydrodimethylconidendrin, and dehydrodimethylretrodendrin. J Org Chem 1971; 36: 3450-3.
104. Kuo YH, Yu MT. A new lignan, formosalactone, from the bark of Juniperus formosana hay. var. concolor hay. Heterocycles 1993; 36: 529-535.
105. Dantzig A, LaLonde RT, Ramdayal F, Shepard RL, Yanai K, Zhang M. Cytotoxic responses to aromatic ring and configurational variations in alpha-conidendrin, podophyllotoxin, and sikkimotoxin derivatives. J Med Chem 2001; 44: 180-5.
106. Kawazoe K, Yutani A, Tamemoto K, Yuasa S, Shibata H, Higuti T, et al. Phenylnaphthalene compounds from the subterranean part of Vitex rotundifolia and their antibacterial activity against methicillin-resistant Staphylococeus aureus. J Nat Prod 2001; 64: 588-91.
107. Chang CW, Lin MT, Lee SS, Liu KC, Hsu FL, Lin JY. Differential inhibition of reverse transcriptase and cellular DNA polymerase-alpha activities by lignans isolated from Chinese herbs, Phyllanthus myrtifolius Moon, and tannins from Lonicera japonica Thunb and Castanopsis hystrix. Antiviral Res 1995; 27: 367-74.
108. Meresse P, Magiatis P, Bertounesque E, Monneret C. Synthesis and antiproliferative activity of retroetoposide. Bioorg Med Chem Lett 2003; 13: 4107-9.
109. Tomioka K, Kubota Y, Koga K. Design, synthesis, and antitumor activity-absolute configuration relationships of podophyllotoxin aza-analogues. Tetrahedron 1993; 49: 1891-1900.
110. Lienard P, Quirion JC, Husson HP. Asymmetric synthesis XXVIII: Hydroxylated benzoquinolizidine analogues of podophyllotoxin via the (CN(R, S) method. Tetrahedron 1993; 49: 3995-4006.
111. Arai Y, Enomoto K. Studies on the anti-tumor activity of isoquinoline derivatives. 3. On the relationship between toxicity and chemical constitution of isoquinoline derivatives. Yakugaku Zasshi 1968; 88: 1197-207.
112. Van der Eycken J, Bosmans JP, Van Haver D, Vandewalle M, Hulkenberg A, Veerman W, et al. The synthesis of 4-desoxy-2-azapodophyllotoxins. Tetrahedron Lett 1989; 30: 3873-6.
113. Bosmans JP, Van der Eycken J, Vandewalle M, Hulkenberg A, Van Hes R, Veerman W. The synthesis of 2-azapodophyllotoxins. Tetrahedron Lett 1989; 30: 3877-80.
114. Hitotsuyanagi Y, Yamagami K, Fuji A, Naka Y, Ito Y, Tahara T. Syntheses and biological properties of novel aza-podophyllotoxin analogs prossessing pronounced antitumor activity. Bioorg Med Chem Lett 1995; 5: 1039-42.
115. Hitotsuyanagi Y, Kobayashi M, Morita H, Itokawa H, Takeya K. Synthesis of (-)-4-aza-4-deoxypodophyllotoxin from (-)-podophyllotoxin. Tetrahedron Lett 1999; 40: 9107-10.
116. Couture A, Deniau E, Grandclaudon P, Lebrun S, Leonce S, Renard P, et al. First synthesis and pharmacological evaluation of benzoindolizidine and benzoquinolizidine analogues of alpha- and beta-peltatin. Bioorg Med Chem 2000; 8: 2113-25.
117. Capilla AS, Sanchez I, Caignard DH, Renard P, Pujol MD. Antitumor agents. Synthesis and biological evaluation of new compounds related to podophyllotoxin, containing the 2, 3-dihydro-1, 4-benzodioxin system. Eur J Med Chem 2001; 36: 389-93
118. Ramdayal FD, Kiemle DJ, LaLonde RT. Directed, DDQ-promoted benzylic oxygenations of tetrahydronaphthalenes. J Org Chem 1999; 64: 4607-9.
119. LaLonde RT, Ramdayal F, Sarko A, Yanai K, Zhang M. Modes of methyleneoxy bridging and their effect on tetrahydronaphthalene lignan cytotoxicity. J Med Chem 2003; 46: 1180-90.
120. van Maanen JM, de Vries J, Pappie D, van den Akker E, Lafleur VM, Retel J, et al. Cytochrome P-450-mediated O-demethylation: a route in the metabolic activation of etoposide (VP-16-213). Cancer Res 1987; 47: 4658-62.
121. Haim N, Nemec J, Roman J, Sinha BK. Peroxidase-catalyzed metabolism of etoposide (VP-16-213) and covalent binding of reactive intermediates to cellular macromolecules. Cancer Res 1987; 47: 5835-40.
122. Wozniak AJ, Glisson BS, Hande KR, Ross WE. Inhibition of etoposide-induced DNA damage and cytotoxicity in L1210 cells by dehydrogenase inhibitors and other agents. Cancer Res 1984; 44: 626-32.
123. Zhang YL, Shen YC, Wang ZQ, Chen HX, Guo X, Cheng YC, et al. Antitumor agents, 130, Novel 4 beta-arylamino derivatives of 3′, 4′-didemethoxy-3′, 4′-dioxo-4-deoxypodophyllotoxin as potent inhibitors of human DNA topoisomerase II. J Nat Prod 1992; 55: 1100-11.
124. Saulnier MG, Vyas DM, Langley DR, Doyle TW, Rose WC, Crosswell AR, et al. E-ring desoxy analogues of etoposide. J Med Chem 1989; 32: 1418-20.
125. Berkowitz BD, Maeng JH, Dantzig AH, Shepard RL, Norman BH. Chemoenzymatic and ring E-modular approach to the (-)-podophyllotoxin skeleton. Synthesis of 3′, 4′, 5′-tridemethoxy-(-)-podophyllotoxin. J Am Chem Soc 1996; 118: 9426-7.
126. Saulnier MG, LeBoulleuc KL, Long BH, Vyas DM, Crosswell AR, Doyle TW. Synthesis of biological evaluation of 4′-deshydroxy-4′-methyl etoposide and teniposide analogs. Bioorg Med Chem Lett 1992; 2: 1213-8.
127. Castro MA, Miguel dei Corral JM, Gordaliza M, Gomez-Zurita MA, de la Puente ML, Betancur-Galvis LA, et al. Synthesis, cytotoxicity and antiviral activity of podophyllotoxin analogues modified in the E-ring. Eur J Med Chem 2003; 38: 899-911.
128. Hitotsuyanagi Y, Kobayashi M, Fukuyo M, Takeya K, Itokawa H. A facile synthesis of the 4-aza-analogs of 1-arylnaphthalene lignans chinensin, justicidin B, and Taiwanin C. Tetrahedron Lett 1997; 38: 8295-6.
129. Tratrat C, Giorgi-Renault S, Husson HP. A multicomponent reaction for the one-pot synthesis of 4-aza-2, 3-didehydropodophyllotoxin and derivatives. Org Lett 2002; 4: 3187-9.
130. Mohamadi FR, Nigel GJ, Guida WC, Liskamp R, Lipton M, Caufield C, et al. MacroModel-an integrated software system for modeling organic and bioorganic molecules using molecular mechanics. J Comput Chem 1990; 11: 440-67.
131. Andersen KV, Buchardt O, Hansen HF, Jensen RB, Larsen S. Inclusion complexes with podophyllotoxin, structural characterization and chiral recognition. J Chem Soc Perkin Trens 2 1990; 1871-9.
132. Hitotsuyanagi Y, Fukuyo M, Tsuda K, Kobayashi M, Ozeki A, Itokawa H, et al. 4-Aza-2, 3-dehydro-4-deoxypodophyllotoxins: simple aza-podophyllotoxin analogues possessing potent cytotoxicity. Bioorg Med Chem Lett 2000; 10: 315-7.
133. Andoh T, Ishii K, Suzuki Y, Ikegami Y, Kusunoki Y, Takemoto Y, Okada K. Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc Natl Acad Sci USA, 1987; 84: 5565-9.
134. Chang JY, Dethlefsen LA, Barley LR, Zhou BS, Cheng YC. Characterization of camptothecin-resistant Chinese hamster lung cells. Biochem Pharmacol 1992; 43: 2443-52.
135. Eng WK, McCabe FL, Tan KB, Mattern MR, Hofmann GA, Woessner RD, et al. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content. Mol Pharmacol 1990; 38: 471-80.
136. Oguro M, Seki Y, Okada K, Andoh T. Collateral drug sensitivity induced in CPT-11 (a novel derivative of camptothecin)-resistant cell lines. Biomed Pharmacother 1990; 44: 209-16.
137. Sugimoto Y, Tsukahara S, Oh-hara T, Liu LF, Tsuruo T. Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. Cancer Res 1990; 50: 7962-5.
138. Tanizawa A, Pommier Y. Topoisomerase I alteration in a camptothecin-resistant cell line derived from Chinese hamster DC3F cells in culture. Cancer Res 1992; 52: 1848-54.
139. Ferguson PJ, Fisher MH, Stephenson J, Li DH, Zhou BS, Cheng YC. Combined modalities of resistance in etoposide-resistant human KB cell lines. Cancer Res 1988; 48: 5956-64.
140. Chang JY, Guo X, Chen HX, Jiang Z, Fu Q, Wang HK, et al. Unique biochemical, cytotoxic, and antitumor activity of camptothecin and 4beta-amino-4′-O-demethylepipodophyllotoxin conjugates. Biochem Pharmacol 2000; 59: 497-508.
141. Shi Q, Wang HK, Bastow KF, Tachibana Y, Chen K, Lee FY, et al. Antitumor agents 210. Synthesis and evaluation of taxoid-epipodophyllotoxin conjugates as novel cytotoxic agents. Bioorg Med Chem 2001; 9: 2999-3004.
142. Gaj CL, Anyanwutaku I, Chang YH, Cheng YC. Decreased drug accumulation without increased drug efflux in a novel MRP-overexpressing multidrug-resistant cell line. Biochem Pharmacol 1998; 55: 1199-211.
143. Mathew AE, Mejillano MR, Nath JP, Himes RH, Stella VJ. Synthesis and evaluation of some water-soluble prodrugs and derivatives of taxol with antitumor activity, J Med Chem 1992; 35: 145-51.
144. Long BH, Casazza AM. Structure-activity relationships of VP-16 analogues. Cancer Chemother Pharmacol 1994; 34: S26-31.
145. Kim Y, You YJ, Nam NH, Ahn BZ. Prodrugs of 4′-demethyl-4-deoxypodophyllotoxin: synthesis and evaluation of the antitumor activity. Bioorg Med Chem Lett 2002; 12: 3435-8.
146. You YJ, Kim Y, Nam NH, Bang SC, Ahn BZ. Alkyl and carboxylalkyl esters of 4′-demethyl-4-deoxypodophyllotoxin: synthesis, cytotoxic, and antitumor activity. Eur J Med Chem 2004; 39: 189-93.
147. Igarashi M, Miyazawa T. Newly recognized cytotoxic effect of conjugated trienoic fatty acids on cultured human tumor cells. Cancer Lett 2000; 148: 173-9.
148. Zhu YP, Su ZW, Li CH. Growth-inhibition effects of oleic acid, linoleic acid, and their methyl esters on transplanted tumors in mice. J Natl Cancer Inst 1989; 81: 1302-6.
149. Ito H, Kasama K, Naruse S, Shimura K. Antitumor effect of pahnitoleic acid on Ehrlich ascites tumor. Cancer Lett 1982; 17: 197-203.
150. Bradley MO, Webb NL, Anthony FH, Devanesan P, Witman PA, Hemamalini S, et al. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel. Clin Cancer Res 2001; 7: 3229-38.
151. You YJ, Kim Y, Nam NH, Ahn BZ. Antitumor activity of unsaturated fatty acid esters of 4′-demethyldeoxypodophyllotoxin. Bioorg Med Chem Lett 2003; 13: 2629-32.
152. Redden P, Douglas JE, Burke MJ, Horrobin DF. In vitro hydrolysis of polyunsaturated fatty acid N-acyloxymethyl derivatives of theophylline, Int J Pharm 1998; 165: 87-96.
153. Demchik LL, Sloane BF. In: Turk A Ed, Proteases: new perspectives. Basel, Birkhauser Verlag 1999; 109-24.
154. Mai J, Waisman DM, Sloane BF. Cell surface complex of cathepsin B/annexin II tetramer in malignant progression. Biochim Biorphys Acta 2000; 1477: 215-30.
155. Thomssen C, Schmitt M, Goretzki L, Oppelt P, Pache L, Dettmar P, et al. Prognostic value of the cysteine proteases cathepsins B and cathepsin L in human breast cancer. Clin Cancer Res 1995; 1: 741-6.
156. Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000; 57: 25-40.
157. Dubowchik GM, Walker MA. Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs. Pharmacol Ther 1999; 83: 67-123.
158. Carl PL, Chakravarty PK, Katzenellenbogen JA, Weber MJ. Protease-activated "prodrugs" for cancer chemotherapy. Proc Natl Acad Sci USA 1980; 77: 2224-8.
159. Chakravarty PK, Carl PL, Weber MJ, Katzenellenbogen JA. Plasmin-activated prodrugs for cancer chemotherapy. 1. Synthesis and biological activity of peptidylacivicin and peptidylphenylenediamine mustard. J Med Chem 1983; 26: 633-8.
160. Chakravarty PK, Carl PL, Weber MJ, Katzenellenbogen JA. Plasmin-activated prodrugs for cancer chemotherapy. 2. Synthesis and biological activity of peptidyl derivatives of doxorubicin. J Med Chem 1983; 26: 638-44.
161. Dubowchik GM, Firestone RA. Cathepsio B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin. Bioorg Med Chem Lett 1998; 8: 3341-6.
162. de Groot FM, de Bart AC, Verheijen JH, Scheeren HW. Synthesis and biological evaluation of novel prodrugs of anthracyclines for selective activation by the tumor-associated protease plasmin. J Med Chem 1999; 42: 5277-83.
163. de Groot FM, van Berkom LW, Scheeren HW. Synthesis and biological evaluation of 2′-carbamate-linked and 2′-carbonate-linked prodrugs of paclitaxel: selective activation by the tumor-associated protease plasmin. J Med Chem 2000; 43: 3093-102.
164. de Groot FM, Loos WJ, Koekkoek R, van Berkom LW, Busscher GF, Seelen AE, et al. Elongated multiple electronic cascade and cyclization spacer systems in activatible anticancer prodrugs for enhanced drug release. J Org Chem 2001; 66: 8815-30.
165. Greenwald RB, Pendri A, Conover CD, Zhao H, Choe YH, Martinez A, et al. Drug delivery systems employing 1, 4- or 1, 6-elimination: poly(ethylene glycol) prodrugs of amine-containing compounds. J Med Chem 1999; 42: 3657-67.
166. Putnam DA, Shiah JG, Kopecek J. Intracellularly biorecognizable derivatives of 5-fluorouracil. Implications for site-specific delivery in the human condition. Biochem Pharmacol 1996; 52: 957-62.
167. Toki BE, Cerveny CG, Wahl AF, Senter PD. Protease-mediated fragmentation of p-amidobenzyl ethers: a new strategy for the activation of anticancer prodrugs. J Org Chem 2002; 67: 1866-72.
168. Bosslet K, Straub R, Blumrich M, Czech J, Gerken M, Sperker B, et al. Elucidation of the mechanism enabling tumor selective prodrug monotherapy. Cancer Res 1998; 58: 1195-201.
169. Jikai J, Shamis M, Huebener N, Schroeder U, Wrasidlo W, Wenkel J, et al. Neuroblastoma directed therapy by a rational prodrug design of etoposide as a substrate for tyrosine hydroxylase. Cancer Lett 2003; 197: 219-24.
170. Nicolaou KC, Li T, Nakada M, Hummel CW, Hiatt A, Wrasidlo W. A rationally designed molecule with extremely potent and selective DNA cleaving properties and apoptosis inducing activity. Angew Chem Int Ed 1994; 33: 183-6.
171. Niethammer A, Gaedicke G, Lode HN, Wrasidlo W. Synthesis and preclinical characterization of a paclitaxel prodrug with improved antitumor activity and water solubility. Bioconjug Chem 2001; 12: 414-20.
172. Wrasidlo W, Schroder U, Bernt K, Hubener N, Shabat D, Gaedicke G, et al. Synthesis, hydrolytic activation and cytotoxicity of etoposide prodrugs. Bioorg Med Chem Lett 2002; 12: 557-60.
173. Satoh T, Hosokawa M. The mammalian carboxylesterases: from molecules to functions. Annu Rev Pharmacol Toxicol 1998; 38: 257-88.
174. Lange B, Schroeder U, Huebener N, Jikai J, Wenkel J, Strandsby A, et al. Rationally designed hydrolytically activated etoposide prodrugs, a novel strategy for the treatment of neuroblastoma. Cancer Lett 2003; 197: 225-30.
175. Schroeder U, Bernt KM, Lange B, Wenkel J, Jikai J, Shabat D, et al. Hydrolytically activated etoposide prodrugs inhibit MDR-1 function and eradicate established MDR-1 multidrug-resistant T-cell leukemia. Blood 2003; 102: 246-53.
176. Glennie MJ, Johnson PW. Clinical trials of antibody therapy. Immunol Today 2000; 21: 403-10.
177. Hoogenboom HR, Chames P. Natural and designer binding sites made by phage display technology. Immunol Today 2000; 21: 371-8.
178. Little M, Kipriyanov SM, Le Gall F, Moldenhauer G. Of mice and men: hybridoma and recombinant antibodies. Immunol Today 2000; 21: 364-70.
179. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001; 1: 118-29.
180. Shabat D, Lode HN, Pertl U, Reisfeld RA, Rader C, Lerner RA, et al. In vivo activity in a catalytic antibody-prodrug system: antibody catalyzed etoposide prodrug activation for selective chemotherapy. Proc Natl Acad Sci USA 2001; 98: 7528-33.
181. Wagner J, Lerner RA, Barbas CF 3rd. Efficient aldolase catalytic antibodies that use the enamine mechanism of natural enzymes. Science 1995; 270: 1797-800.
182. Barbas CF3rd, Heine A, Zhong G, Hoffmann T, Gramatikova S, Bjornestedt R, et al. Immune versus natural selection: antibody aldolases with enzymic rates but broader scope. Science 1997; 278: 2085-92.
183. Shabat D, Rader C, List B, Lerner RA, Barbas CF 3rd. Multiple event activation of a generic prodrug trigger by antibody catalysis. Proc Natl Acad Sci USA 1999; 96: 6925-30.
184. Wentworth P, Datta A, Blakey D, Boyle T, Partridge LJ, Blackburn GM. Toward antibody-directed "abzyme" prodrug therapy, ADAPT: carbamate prodrug activation by a catalytic antibody and its in vitro application to human tumor cell killing. Proc Natl Acad Sci USA 1996; 93: 799-803.
185. Campbell DA, Gong B, Kochersperger LM, Yonkovich S, Gallop MA, Schultz PG. Antibody-catalyzed prodrug activation. J Am Chem Soc 1994; 116: 2165-6.
186. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Controlled Release 2000; 65: 271-84.
187. Vasey PA, Kaye SB, Morrison R, Twelves C, Wilson P, Duncan R, et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Clin Cancer Res 1999; 5: 83-94.
188. Julyan PJ, Seymour LW, Ferry DR, Daryani S, Boivin CM, Doran J, et al. Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine. J Controlled Release 1999; 57: 281-90.
189. Fraier D, Cenacchi V, Frigerio E. Determination of a new polymer-bound paclitaxel derivative (PNU 166945), free paclitaxel and 7-epipaclitaxel in dog plasma and urine by reversed-phase high-performance liquid chromatography with UV detection. J Chromatogr A 1998; 797: 295-303.
190. de Jonge MJ, Punt CJ, Gelderblom AH, Loos WJ, van Beurden V, Planting AS, et al. Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumors. J Clin Oncol 1999; 17: 2219-26.
191. Satchi-Fainaro R, Wrasidlo W, Lode HN, Shabat D. Synthesis and characterization of a catalytic antibody-HPMA copolymer-conjugate as a tool for tumor selective prodrug activation. Bioorg Meti Chem 2002; 10: 3023-9.
192. Ganapathi R, Vaziri SA, Tabata M, Takigawa N, Grabowski DR, Bukowski RM, et al Inhibition of NF-kappaB and proteasome activity in tumors: can we improve the therapeutic potential of topoisomerase I and topoisomerase II poisons. Curr Pharm Design 2002; 8(22): 1945-58.
193. Nagaraja V, Sikder D, Jain P. DNA topoisomerase I from mycobacteria - a potential drug target. Curr Pharm Design 2002; 8(22): 1995-2007.
194. Zunino F, Dallavalleb S, Laccabuea D, Berettaa G, Merlinib L. Pratesi G. Current status and perspectives in the development of camptothecins. Curr Pharm Design 2002; 8(27): 2505-20.